Cero Therapeutics Files 10-K Amendment

Ticker: CEROW · Form: 10-K/A · Filed: Apr 28, 2025 · CIK: 1870404

Sentiment: neutral

Topics: amendment, annual-report, biotech

TL;DR

Cero Therapeutics filed its 2024 10-K amendment. Check for updates.

AI Summary

Cero Therapeutics Holdings, Inc. filed an amendment (Amendment No. 1) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. This filing, dated April 28, 2025, provides updated information for the period ending December 31, 2024. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This amendment provides updated financial and operational information for Cero Therapeutics Holdings, Inc., crucial for investors and stakeholders to assess the company's performance and outlook for the fiscal year 2024.

Risk Assessment

Risk Level: low — This is a routine amendment to a previously filed annual report, not indicating new material adverse events.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 10-K/A filing?

This is Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2024, indicating updates or corrections to the original filing.

When was Cero Therapeutics Holdings, Inc. formerly known as Phoenix Biotech Acquisition Corp.?

The company's name was changed from Phoenix Biotech Acquisition Corp. on June 30, 2021.

What is the primary business of Cero Therapeutics Holdings, Inc.?

The company is classified under Biological Products (No Diagnostic Substances) [2836].

Where is Cero Therapeutics Holdings, Inc. located?

The company's business and mailing address is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.

What is the SEC file number for Cero Therapeutics Holdings, Inc.?

The SEC file number is 001-40877.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 28, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing